{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:12:28Z","timestamp":1789783948879,"version":"4.0.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["DP120100064"],"award-info":[{"award-number":["DP120100064"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["DP180103875"],"award-info":[{"award-number":["DP180103875"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Health and Medical Research Council (NHMRC) of Australia","award":["1141921"],"award-info":[{"award-number":["1141921"]}]},{"name":"National Health and Medical Research Council (NHMRC) of Australia","award":["1080001"],"award-info":[{"award-number":["1080001"]}]},{"name":"National Health and Medical Research Council (NHMRC) of Australia","award":["1173027"],"award-info":[{"award-number":["1173027"]}]},{"name":"National Health and Medical Research Council (NHMRC) of Australia","award":["1135955"],"award-info":[{"award-number":["1135955"]}]},{"name":"National Health and Medical Research Council (NHMRC) of Australia","award":["1132975"],"award-info":[{"award-number":["1132975"]}]},{"name":"Medicines for Malaria"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Artemisinin derivatives are the leading class of antimalarial drugs due to their rapid onset of action and rapid clearance of circulating parasites. The parasite clearance half-life measures the rate of loss of parasites from blood after treatment, and this is currently used to assess antimalarial activity of novel agents and to monitor resistance. However, a number of recent studies have challenged the use of parasite clearance to measure drug activity, arguing that many circulating parasites may be nonviable.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Plasmodium falciparum\u2013infected subjects (n = 10) in a malaria volunteer infection study were administered a single dose of artesunate (2 mg\/kg). Circulating parasite concentration was assessed by means of quantitative polymerase chain reaction (qPCR). Parasite viability after artesunate administration was estimated by mathematical modeling of the ex vivo growth of parasites collected from subjects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We showed that in artemisinin-sensitive infection, viable parasites declined to &amp;lt;0.1% of baseline within 8 hours after artesunate administration, while the total number of circulating parasites measured with quantitative polymerase chain reaction remained unchanged. In artemisinin-resistant infections over the same interval, viable parasites declined to 51.4% (standard error of the mean, 4.6%) of baseline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These results demonstrate that in vivo drug activity of artesunate is faster than is indicated by the parasite clearance half-life.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiaa678","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T11:13:32Z","timestamp":1603451612000},"page":"2154-2163","source":"Crossref","is-referenced-by-count":18,"title":["Parasite Viability as a Superior Measure of Antimalarial Drug Activity in Humans"],"prefix":"10.1093","volume":"223","author":[{"given":"Maria","family":"Rebelo","sequence":"first","affiliation":[{"name":"QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Pawliw","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Gower","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lachlan","family":"Webb","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Mitchell","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuleima","family":"Pava","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca E","family":"Watts","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles P","family":"Davenport","sequence":"additional","affiliation":[{"name":"Kirby Institute, University of New South Wales (Sydney), Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S","family":"McCarthy","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2663-1551","authenticated-orcid":false,"given":"David S","family":"Khoury","sequence":"additional","affiliation":[{"name":"Kirby Institute, University of New South Wales (Sydney), Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,29]]},"reference":[{"key":"2021061601413401600_CIT0001","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0140-6736(82)90268-9","article-title":"Antimalarial activity of mefloquine and qinghaosu","volume":"2","author":"Jiang","year":"1982","journal-title":"Lancet"},{"key":"2021061601413401600_CIT0002","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMoa0808859","article-title":"Artemisinin resistance in Plasmodium falciparum malaria","volume":"361","author":"Dondorp","year":"2009","journal-title":"N Engl J Med"},{"key":"2021061601413401600_CIT0003","volume-title":"Methods for surveillance of antimalarial drug efficacy","author":"World Health Organization","year":"2009"},{"key":"2021061601413401600_CIT0004","doi-asserted-by":"crossref","first-page":"e21914","DOI":"10.1371\/journal.pone.0021914","article-title":"A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs","volume":"6","author":"McCarthy","year":"2011","journal-title":"PLoS One"},{"key":"2021061601413401600_CIT0005","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa1315860","article-title":"Spiroindolone KAE609 for falciparum and vivax malaria","volume":"371","author":"White","year":"2014","journal-title":"N Engl J Med"},{"key":"2021061601413401600_CIT0006","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1473-3099(17)30171-8","article-title":"Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a\/1b randomised study","volume":"17","author":"McCarthy","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2021061601413401600_CIT0007","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12936-016-1675-x","article-title":"New developments in anti-malarial target candidate and product profiles","volume":"16","author":"Burrows","year":"2017","journal-title":"Malar J"},{"key":"2021061601413401600_CIT0008","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S1473-3099(19)30611-5","article-title":"Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a\/b trial","volume":"20","author":"Gaur","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2021061601413401600_CIT0009","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.pt.2020.02.005","article-title":"Malaria parasite clearance: what are we really measuring?","volume":"36","author":"Khoury","year":"2020","journal-title":"Trends Parasitol"},{"key":"2021061601413401600_CIT0010","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/1475-2875-10-278","article-title":"The parasite clearance curve","volume":"10","author":"White","year":"2011","journal-title":"Malar J"},{"key":"2021061601413401600_CIT0011","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1073\/pnas.1006113108","article-title":"Intrahost modeling of artemisinin resistance in Plasmodium falciparum","volume":"108","author":"Saralamba","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021061601413401600_CIT0012","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1208\/s12248-014-9647-y","article-title":"Making the most of clinical data: reviewing the role of pharmacokinetic-pharmacodynamic models of anti-malarial drugs","volume":"16","author":"Simpson","year":"2014","journal-title":"AAPS J"},{"key":"2021061601413401600_CIT0013","doi-asserted-by":"crossref","first-page":"6419","DOI":"10.1128\/AAC.00482-15","article-title":"Altering antimalarial drug regimens may dramatically enhance and restore drug effectiveness","volume":"59","author":"Kay","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2021061601413401600_CIT0014","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12936-017-1731-1","article-title":"Malaria parasite clearance","volume":"16","author":"White","year":"2017","journal-title":"Malar J"},{"key":"2021061601413401600_CIT0015","doi-asserted-by":"crossref","first-page":"e01068-18","DOI":"10.1128\/AAC.01068-18","article-title":"Investigating the efficacy of triple artemisinin-based combination therapies for treating Plasmodium falciparum malaria patients using mathematical modeling","volume":"62","author":"Dini","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021061601413401600_CIT0016","doi-asserted-by":"crossref","first-page":"e00590-19","DOI":"10.1128\/AAC.00590-19","article-title":"Improving methods for analyzing antimalarial drug efficacy trials: molecular correction based on length-polymorphic markers msp-1, msp-2, and glurp","volume":"63","author":"Jones","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021061601413401600_CIT0017","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/infdis\/jiy649","article-title":"Optimal treatments for severe malaria and the threat posed by artemisinin resistance","volume":"219","author":"Jones","year":"2019","journal-title":"J Infect Dis"},{"key":"2021061601413401600_CIT0018","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/S1473-3099(19)30426-8","article-title":"PCR correction strategies for malaria drug trials: updates and clarifications","volume":"20","author":"Felger","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2021061601413401600_CIT0019","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.pt.2013.04.001","article-title":"Antidogmatic approaches to artemisinin resistance: reappraisal as treatment failure with artemisinin combination therapy","volume":"29","author":"Krishna","year":"2013","journal-title":"Trends Parasitol"},{"key":"2021061601413401600_CIT0020","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.pt.2013.05.002","article-title":"Artemisinin resistance in Plasmodium falciparum: what is it really?","volume":"29","author":"Ferreira","year":"2013","journal-title":"Trends Parasitol"},{"key":"2021061601413401600_CIT0021","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1475-2875-13-62","article-title":"Pharmacological considerations in the design of anti-malarial drug combination therapies - is matching half-lives enough?","volume":"13","author":"Hastings","year":"2014","journal-title":"Malar J"},{"key":"2021061601413401600_CIT0022","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1128\/AAC.00481-15","article-title":"How robust are malaria parasite clearance rates as indicators of drug effectiveness and resistance?","volume":"59","author":"Hastings","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2021061601413401600_CIT0023","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/cid\/ciw501","article-title":"Artemisinin resistance and the blame game","volume":"63","author":"Krishna","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021061601413401600_CIT0024","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/cid\/ciw581","article-title":"The importance of scientific debate in the identification, containment, and control of artemisinin resistance","volume":"63","author":"Hastings","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021061601413401600_CIT0025","doi-asserted-by":"crossref","first-page":"e1003203","DOI":"10.1371\/journal.pmed.1003203","article-title":"Safety and parasite clearance of artemisinin-resistant Plasmodium falciparum infection: a pilot and a randomised volunteer infection study in Australia","volume":"17","author":"Watts","year":"2020","journal-title":"PLoS Med"},{"key":"2021061601413401600_CIT0026","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1475-2875-10-48","article-title":"A real-time, quantitative PCR method using hydrolysis probes for the monitoring of Plasmodium falciparum load in experimentally infected human volunteers","volume":"10","author":"Rockett","year":"2011","journal-title":"Malar J"},{"key":"2021061601413401600_CIT0027","first-page":"1","article-title":"Culturing of erythrocytic asexual stages of Plasmodium falciparum and P. vivax.","volume-title":"Methods in malaria research","author":"Mphande","year":"2008","edition":"5th ed"},{"key":"2021061601413401600_CIT0028","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/s12936-015-0874-1","article-title":"Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis","volume":"14","author":"Abdulla","year":"2015","journal-title":"Malar J"},{"key":"2021061601413401600_CIT0029","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S1471-4922(02)02373-5","article-title":"The assessment of antimalarial drug efficacy","volume":"18","author":"White","year":"2002","journal-title":"Trends Parasitol"},{"key":"2021061601413401600_CIT0030","doi-asserted-by":"crossref","first-page":"12132","DOI":"10.1038\/s41598-017-12483-4","article-title":"Split dosing of artemisinins does not improve antimalarial therapeutic efficacy","volume":"7","author":"White","year":"2017","journal-title":"Sci Rep"},{"key":"2021061601413401600_CIT0031","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S1473-3099(13)70252-4","article-title":"Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies","volume":"13","author":"Witkowski","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2021061601413401600_CIT0032","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1128\/AAC.41.7.1413","article-title":"Assessment of the pharmacodynamic properties of antimalarial drugs in vivo","volume":"41","author":"White","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2021061601413401600_CIT0033","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1073\/pnas.1211205110","article-title":"Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia","volume":"110","author":"Takala-Harrison","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021061601413401600_CIT0034","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ijpddr.2012.01.001","article-title":"Artemisinin resistance in Plasmodium falciparum: a process linked to dormancy?","volume":"2","author":"Cheng","year":"2012","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"2021061601413401600_CIT0035","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1128\/AAC.05540-11","article-title":"Phenotypic and genotypic analysis of in vitro-selected artemisinin-resistant progeny of Plasmodium falciparum","volume":"56","author":"Tucker","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2021061601413401600_CIT0036","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1086\/656476","article-title":"Artemisinin-induced dormancy in Plasmodium falciparum: duration, recovery rates, and implications in treatment failure","volume":"202","author":"Teuscher","year":"2010","journal-title":"J Infect Dis"},{"key":"2021061601413401600_CIT0037","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4269\/ajtmh.1993.49.106","article-title":"Falciparum malaria: differential effects of antimalarial drugs on ex vivo parasite viability during the critical early phase of therapy","volume":"49","author":"Watkins","year":"1993","journal-title":"Am J Trop Med Hyg"},{"key":"2021061601413401600_CIT0038","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4269\/ajtmh.1995.53.303","article-title":"Parasite viability during treatment of severe falciparum malaria: differential effects of artemether and quinine","volume":"53","author":"Murphy","year":"1995","journal-title":"Am J Trop Med Hyg"},{"key":"2021061601413401600_CIT0039","doi-asserted-by":"crossref","first-page":"e1779","DOI":"10.1371\/journal.pone.0001779","article-title":"Open-label comparative clinical study of chlorproguanil-dapsone fixed dose combination (LapdapTM) alone or with three different doses of artesunate for uncomplicated Plasmodium falciparum malaria","volume":"3","author":"Wootton","year":"2008","journal-title":"PLoS One"},{"key":"2021061601413401600_CIT0040","doi-asserted-by":"crossref","first-page":"7701","DOI":"10.1073\/pnas.1618939114","article-title":"Host-mediated impairment of parasite maturation during blood-stage Plasmodium infection","volume":"114","author":"Khoury","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021061601413401600_CIT0041","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.1128\/AEM.01763-14","article-title":"Dead or alive: molecular assessment of microbial viability","volume":"80","author":"Cangelosi","year":"2014","journal-title":"Appl Environ Microbiol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa678\/35174754\/jiaa678.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/223\/12\/2154\/38655853\/jiaa678.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/223\/12\/2154\/38655853\/jiaa678.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T01:43:12Z","timestamp":1623807792000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/223\/12\/2154\/5943003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,29]]},"references-count":41,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,10,29]]},"published-print":{"date-parts":[[2021,6,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa678","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,15]]},"published":{"date-parts":[[2020,10,29]]}}}